CARISMA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 USD | +2.92% |
|
-4.73% | -51.88% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 15.62M | Sales 2025 * | 12.96M | Capitalization | 58.58M |
|---|---|---|---|---|---|
| Net income 2024 * | -57M | Net income 2025 * | -68M | EV / Sales 2024 * | 3.75 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
-1.12
x | P/E ratio 2025 * |
-1.08
x | Employees | 107 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.92% | ||
| 1 week | -4.73% | ||
| Current month | -13.50% | ||
| 1 month | -16.57% | ||
| 3 months | -38.70% | ||
| 6 months | -43.37% | ||
| Current year | -51.88% |
1 week
1.35
1.53
1 month
1.351.91
Current year
1.353.06
1 year
1.359.77
3 years
1.359.77
5 years
1.359.77
10 years
1.359.77
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
| Director/Board Member | 66 | 22-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 1.41 | +2.92% | 223,335 |
| 24-05-16 | 1.37 | -2.14% | 187,493 |
| 24-05-15 | 1.4 | -4.11% | 224,573 |
| 24-05-14 | 1.46 | -1.35% | 180,190 |
| 24-05-13 | 1.48 | 0.00% | 249,490 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.41
USD
Average target price
7.5
USD
Spread / Average Target
+431.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.88% | 58.58M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.84B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- CARM Stock